The stock of AIM ImmunoTech Inc (AMEX:AIM) last traded at $0.47, up 6.32% from the previous session.
AIM stock price is now 16.22% away from the 50-day moving average and -6.27% away from the 200-day moving average. The market capitalization of the company currently stands at $23.00M.
In other news, BRYAN NANCY, Director bought 38,462 shares of the company’s stock on Mar 21 ’24. The stock was bought for $15,000 at an average price of $0.39. Upon completion of the transaction, the Director now directly owns 38,462 shares in the company, valued at $18077.14. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 15 ’24, Director APPELROUTH STEWART bought 90,910 shares of the business’s stock. A total of $30,000 was incurred on buying the stock at an average price of $0.33. This leaves the insider owning 239,765 shares of the company worth $0.11 million. A total of 9.19% of the company’s stock is owned by insiders.
During the past 12 months, AIM ImmunoTech Inc has had a low of $0.32 and a high of $0.75. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 4.82, and a quick ratio of 4.82. The fifty day moving average price for AIM is $0.4064 and a two-hundred day moving average price translates $0.5031 for the stock.
The latest earnings results from AIM ImmunoTech Inc (AMEX: AIM) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, missing analysts’ expectations of -$0.11 by -0.05. This compares to -$0.13 EPS in the same period last year. The net profit margin was -10764.25% and return on equity was -63.63% for AIM. The company reported revenue of $46000.0 for the quarter, compared to $21000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 119.05 percent. For the current quarter, analysts expect AIM to generate $40k in revenue.
